Health
Nigeria, Others to Receive 220 million J&J Vaccine Doses
By Adedapo Adesanya
Nigeria and the other 54-member states of the African Union (AU) will receive the supply of up to 220 million doses of the Johnson & Johnson single-shot vaccine by the end of 2022.
The expected delivery of the J&J vaccine doses followed an agreement signed by the United Nations Children Fund (UNICEF) with Janssen Pharmaceutica NV, which will see some 35 million doses delivered by the end of this year, UNICEF stated in a statement issued in New York.
The agreement between UNICEF and Janssen Pharmaceutica NV will help implement the Advance Purchase Commitment (APC) signed between the African Vaccine Acquisition Trust (AVAT) and Janssen last March.
That agreement secured an option to order another 180 million doses, bringing the maximum access up to a total of 400 million doses by the end of 2022.
The AU established AVAT in November 2020 to deliver COVID-19 vaccines to the African continent, with a goal of vaccinating 60 per cent of the population of member-states.
Under the plan, the African Export-Import Bank (Afreximbank) and AVAT have signed a cooperation agreement on behalf of the AU for the development of an Advance Procurement Commitment (APC) Framework to support member-states access to COVID-19 vaccines.
UNICEF will procure and deliver COVID-19 vaccines on behalf of the AVAT initiative.
Other partners include the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Bank while multiple vaccines are anticipated to be part of the initiative’s portfolio, Janssen’s single-dose vaccine is the first to be included.
“African countries must have affordable and equitable access to COVID-19 vaccines as soon as possible.
“Vaccine access has been unequal and unfair, with less than one per cent of the population of the African continent currently vaccinated against COVID-19 and this cannot continue,” a part of the statement said.
UNICEF Executive Director, Ms Henrietta Fore, further stated that, “UNICEF, with its long history of delivering vaccines all around the world, is supporting global COVID-19 vaccination efforts through AVAT, COVAX, and other channels to maximize supply and access to vaccines.”
Drawing upon decades of experience as the largest single vaccine buyer in the world as it does annually for routine immunization, UNICEF is acting as a procurement and logistics agency on behalf of the AVAT partnership.
UNICEF says it stands ready to facilitate the procurement, transport and delivery of vaccines as soon as they become available and AU member-states are ready to receive them.
UNICEF plans to work with the vaccine industry, freight forwarders and transport companies to get the doses to the communities that need them.
Janssen’s COVID-19 vaccine received a World Health Organisation (WHO) Emergency Use Listing (EUL) on March 12 and is relying on a global supply network to produce the vaccine.
The latest site for production, Aspen Pharmacare in Gqeberha, South Africa, was approved by the WHO in June.
The delivery of the vaccine is expected to begin later in the third quarter of 2021, with allocations to be determined by the Africa Centre for Disease Control (ACDC).
The agreement comes as the African continent faces the steepest surge in COVID-19 cases yet and vaccine supply challenges have left many countries with large unvaccinated populations.
In addition to its role in this partnership, UNICEF is also a key implementing partner for the COVAX Facility led by Gavi, the Vaccine Alliance, WHO, and CEPI.
Under this initiative, UNICEF has contributed to the delivery of more than 100 million doses to 135 countries.
UNICEF’s role in procuring and delivering COVID-19 vaccines on behalf of AVAT will complement and supplement the shared COVAX goal of ensuring equitable access to quality-assured COVID-19 vaccines.
“Vaccinating the world against COVID-19, as the virus continues to spread and mutate, is one of the largest and most complex collective health undertakings the world has ever seen, and we need all hands on deck.
“In the race to defeat this virus, equity is not a ‘nice to have’ — it’s an absolute necessity. This pandemic has cost everyone something, and some people everything.
“Only together can we bring the suffering to an end,” the statement added.
Health
Helical Secures $10m Funding Package for Expansion
By Dipo Olowookere
A $10 million capital has been raised by Helical to support expansion across more top-20 pharma programmes and growth of its deployed science engineering team.
The firm will also use the money to build the compounding evidence layer that improves performance across diseases, as its mission is to make every scientist able to test hypotheses at the speed of inference and to turn in-silico discovery into a reliable engine for R&D throughput.
The funding package was from redalpine, Gradient, BoxGroup, Frst and notable angels, including Aidan Gomez (CEO Cohere), Clement Delangue (CEO HuggingFace) and Mario Goetze (pro soccer player).
Helical has a product known as the virtual AI lab for pharma, an application layer that turns biological foundation models into decision-ready, reproducible in-silico discovery workflows.
The platform has two product surfaces — the Virtual Lab for biologists and translational scientists, and the Model Factory for ML engineers and data scientists — built on the same data, the same models, and the same results.
By putting both sides in the same system, Helical closes the gap between computational predictions and biological decision-making, so teams that traditionally worked in silos can collaborate on the same evidence.
Helical was founded in early 2024. It was created by three school friends who took different paths to the same problem.
Rick Schneider built tech at Amazon and later helped the German enterprise Celonis scale in France and Japan. Maxime Allard led data science teams at IBM before pursuing a PhD focused on reinforcement learning and robotics. Mathieu Klop became a cardiologist and genomics researcher.
When bio foundation models emerged, the trio saw the chance to build the missing application layer that would let pharma teams move from model experimentation to reproducible, production discovery.
“The models alone don’t discover drugs. The system does. Pharma teams need a system that turns foundation models into workflows scientists can run, validate, and defend.
“We built Helical to make in-silico science reproducible at pharma scale, so teams can go from hypothesis to decision in days instead of months,” the co-founder of Helical, Mr Rick Schneider, said.
“We are at a unique point in time where biological foundation models and general language reasoning models are converging.
“We backed Helical because we strongly believe they have what it takes to build the pharma AI orchestration platform that will drive this transition from siloed AI models to integrated virtual AI labs,” the General Partner at redalpine, Mr Daniel Graf, stated.
Health
NARD Suspends Indefinite Strike, Gives FG Fresh Two-Week Ultimatum
By Adedapo Adesanya
The Nigerian Association of Resident Doctors (NARD) has suspended its planned nationwide indefinite strike, granting the federal government a two-week ultimatum to address lingering welfare issues affecting resident doctors across the country.
The decision was taken after an emergency meeting of the association’s National Executive Council on Tuesday, where members reviewed assurances from government representatives and resolved to give dialogue another chance.
NARD said the suspension was informed by “progress made” in negotiations, particularly commitments on the prompt payment of salary arrears, hazard allowances, and steps toward resolving issues surrounding the Medical Residency Training Fund.
The association did not declare a full resolution of the dispute. It noted that the government had shown “renewed willingness” to address the concerns that triggered the strike threat.
The association noted that while these engagements signalled a willingness by the government to resolve the dispute, several critical issues remain outstanding, particularly the delayed payment of promotion arrears, salary arrears, the 2026 Medical Residency Training Fund (MRTF), and the backlog of 19 months’ professional allowance arrears owed to resident doctors.
It also expressed concern over the Federal Government’s decision to halt the implementation of the reviewed PAT, which had earlier triggered widespread dissatisfaction among its members and raised fears of disruption to healthcare services nationwide.
Despite these unresolved issues, NARD said it opted to suspend the strike as a demonstration of goodwill and commitment to ongoing dialogue, while giving the government a two-week window to take concrete, measurable and verifiable steps to meet its demands.
The association insisted on the immediate reversal of the decision affecting the PAT, payment of all outstanding arrears, prompt disbursement of the MRTF, and full settlement of the accumulated professional allowance backlog.
It warned that it would reconvene at the expiration of the ultimatum to assess the level of compliance and determine its next course of action, adding that failure by the government to meet its demands within the stipulated timeframe would result in the resumption of the suspended strike without further notice.
NARD also called on its members nationwide to remain calm, united and resolute, while urging the Federal Government to act swiftly to prevent a potential crisis in the health sector.
The association further appreciated the interventions of the Vice President and other stakeholders, expressing hope that their involvement would lead to the timely resolution of the dispute and help sustain healthcare delivery across the country.
Health
Jacaranda Gets Funds to Expand Affordable Maternal Healthcare in Kenya
By Modupe Gbadeyanka
To expand affordable healthcare in Kenya, Swedfund has invested about $600,000 into Jacaranda Health Limited (Jacaranda Maternity) to support innovations in neonatal intensive care and strengthen Jacaranda’s ability to provide life-saving services to underserved populations.
Jacaranda Maternity provides high-quality maternal health care at more affordable pricing than typical private providers, focusing on women in Nairobi’s low- and middle-income communities.
The new funding will support the opening of new hospitals, upgrading of neonatal care, and improvements to existing facilities.
Maternal and newborn health outcomes in Kenya remain a challenge, with maternal mortality still high despite improvements in skilled birth attendance.
Public health facilities play a central role but face capacity constraints, while access to reliable, quality care varies across regions and income groups.
Private healthcare providers offering essential maternity services at accessible price points can complement public provision.
Jacaranda Maternity aims to expand its network to six hospitals to achieve financial sustainability while scaling its impact. The healthcare provider is a recognised leader in promoting women’s health, with 71 percent of its staff being women, and a track record of effective environmental and social management.
“This investment will help Jacaranda Maternity provide life-saving care to more women and families while furthering Swedfund’s mission to promote inclusive and sustainable healthcare,” a Senior Investment Manager at Swedfund, Audrey Obara, said.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn
